Sachdeva et al.(99. Sachdeva RK, Sharma A, Singh S, Varma S. Spectrum of AIDS defining & non-AIDS defining malignancies in north India. Indian J Med Res. 2016; 143(Suppl):S129-35.) |
2,800 HIV-infected patients |
Analysis of records |
|
To determine the type and frequency of neoplasms in the population studied |
Retrospective cohort |
Franceschi et al.(1010. Franceschi S, Lise M, Clifford GM, Rickenbach M, Levi F, Maspoli M, et al. Changing patterns of cancer incidence in the early- and late-HAART periods: the Swiss HIV cohort study. Br J Cancer. 2010;103(3):416-22.) |
9,429 patients with HIV/AIDS |
Analysis of nine records from Swiss cancer centers |
|
To assess changes in cancer incidence in the pre-HAART, early HAART, and late HAART periods |
Retrospective cohort |
Reed et al.(1111. Reed M, Cosgrove JM, Cindrich R, Parithivel VS, Gad Y, Bangalore M, et al. Ten years later: a single hospital experience with malignancy in HIV/AIDS. J Surg Oncol. 2010;102(3):282-6.) |
5,112 patients with HIV/AIDS and 3,578 patients with HIV/AIDS from a previous study. |
Comparison of information between the current study and the study conducted by the research group ten years earlier |
|
To compare data between the two studies in order to assess trends in neoplasms |
Cohort/ retrospective cohort |
Polesel et al.(1212. Polesel J, Franceschi S, Suligoi B, Crocetti E, Falcini F, Guzzinati S, et al. Cancer incidence in people with AIDS in Italy. Int J Cancer. 2010;127(6):1437-45.) |
21,951 patients diagnosed with AIDS |
Analysis of AIDS records and of Italian cancer data |
|
To estimate changes in cancer incidence in individuals with HIV/AIDS in Italy before and after the introduction of HAART |
Retrospective cohort |
Spagnuolo et al.(1313. Spagnuolo V, Galli L, Salpietro S, Gianotti N, Guffanti M, Cossarini F, et al. Ten-year survival among HIV-1-infected subjects with AIDS or non-AIDS-defining malignancies. Int J Cancer. 2012;130(12):2990-6.) |
6,495 patients with HIV-infected |
Data collection from patients infected with HIV between 1991 and 2010 at a single center |
|
To describe survival in patients with HIV and diagnosis of AIDS-defining and non-AIDS-defining neoplasms |
Retrospective cohort |
Shiels et al.(1414. Shiels MS, Pfeiffer RM, Gail MH, Hall HI, Li J, Chaturvedi AK, et al. Cancer burden in the HIV-infected population in the United States. J Natl Cancer Inst. 2011;103(9):753-62.) |
Number of 883,001 (estimated US population living with AIDS between 1991 and 2005) |
Data analysis of AIDS prevalence and cancer rates |
|
To assess trends in cancer burden among people with AIDS in the US during 1991-2005, which were distributed into pre-HAAT, HAART, and late HAART periods |
Retrospective cohort |
Simard et al.(1515. Simard EP, Pfeiffer RM, Engels EA. Cumulative incidence of cancer among individuals with acquired immunodeficiency syndrome in the United States. Cancer. 2011;117(5):1089-96.) |
472,378 PLHIV/AIDS in 15 US states (1980 and 2008) |
Link of AIDS records with cancer records. |
|
To assess the impact of HAART on trends of mortality and cancer incidence in the population studied |
Retrospective cohort |
Achhra et al.(1616. Achhra AC, Amin J, Law MG, Emery S, Gerstoft J, Gordin FM, et al. Immunodeficiency and the risk of serious clinical endpoints in a well studied cohort of treated HIV-infected patients. AIDS Lond Engl. 2010;24(12):1877-86.) |
Total of 4,111 patients (control group and group using interleukin-2) |
Comparison between data (clinical evaluation, CD4 count and HIV RNA copy count) of patients included in the two groups |
Patients not using interleukin-2 n=1,971 |
To explore the role of antiretroviral therapy and investigate the association between immunodeficiency, viremia and neoplasms |
Retrospective cohort |
Yanik et al.(1717. Yanik EL, Napravnik S, Cole SR, Achenbach CJ, Gopal S, Olshan A, et al. Incidence and timing of cancer in HIV-infected individuals following initiation of combination antiretroviral therapy. Clin Infect Dis Off Publ Infect Dis Soc Am. 2013;57(5):756-64.) |
> 25 thousand PLHIV who started antiretroviral therapy between 1996 and 2011 |
Analysis of records from eight university centers |
|
To assess trends in cancer incidence rates after initiation ofantiretroviral therapy. |
Retrospective cohort |
Franzetti et al.(1818. Franzetti M, Adorni F, Parravicini C, Vergani B, Antinori S, Milazzo L, et al. Trends and predictors of non-AIDS-defining cancers in men and women with HIV infection: a single-institution retrospective study before and after the introduction of HAART. J Acquir Immune Defic Syndr. 2013;62(4):414-20.) |
7,466 PLHIV |
Analysis of patient data from a single center in Milan |
|
To examine the incidence rates and characteristics of non-AIDS-defining neoplasms |
Retrospective cohort |
Cobucci et al.(1919. Cobucci RN, Lima PH, Souza PC, Costa VV, Cornetta MC, Fernandes JV, et al. Assessing the impact of HAART on the incidence of defining and non-defining AIDS cancers among patients with HIV/AIDS: a systematic review. J Infect Public Health. 2015;8(1):1-10. Review.) |
21 selected articles (N>600 thousand PLHIV/AIDS) |
Systematic review using MOOSE guidelines |
|
To assess the impact of HAART on the incidence of AIDS-defining and non-AIDS-defining neoplasms |
Systematic review |
Crum-Cianflone et al.(2020. Crum-Cianflone NF, Wang X, Ganesan A, Okulicz J, Weintrob A, Lalani T, et al. Short Communication: HIV RNA Levels Predict AIDS-Defining and Non-AIDS-Defining Cancers After Antiretroviral Therapy Initiation Among HIV-Infected Adults. AIDS Res Hum Retroviruses. 2015;31(5):514-8.) |
2,238 PLHIV |
Clinical interviews, physical exams, and collection of medical record data |
|
To determine the effect of HIV control on cancer in extensive use of antiretroviral therapy. |
Retrospective cohort |
Castel et al.(2121. Castel AD, Young H, Akiwumi AM, Vargas A, Rogers K, West T, et al. Trends in cancer diagnoses and survival among persons with AIDS in a high HIV prevalence urban area. AIDS Care. 2015;27(7):860-9.) |
8,800 PLAIDS residents of Washington between 1996 and 2006 |
Analysis of Washington AIDS and cancer records during the study period |
|
To assess the incidence and survival rates of cancer in PLAIDS during the early HAART and late HAART era |
Retrospective cohort |
Hernández-Ramírez et al.(2222. Hernández-Ramírez RU, Shiels MS, Dubrow R, Engels EA. Cancer risk in HIV-infected people in the USA from 1996 to 2012: a population-based, registry-linkage study. Lancet HIV. 2017;4(11):e495-504.) |
44,8258 PLHIV |
Analysis of PLHIV records from nine US states and the link with cancer records |
|
To describe the spectrum of cancer risk among HIV-infected people in the US during the HAART era |
Retrospective cohort |
Tanaka et al.(2323. Tanaka LF, Latorre MD, Gutierrez EB, Heumann C, Herbinger KH, Froeschl G. Trends in the incidence of AIDS-defining and non-AIDS-defining cancers in people living with AIDS: a population-based study from São Paulo, Brazil. Int J STD AIDS. 2017;28(12):1190-8.) |
87,109 PLAIDS in São Paulo between 1980 and 2013 |
Link between AIDS and cancer case records in the city of São Paulo |
General population of São Paulo |
To analyze trends in cancer incidence among residents of São Paulo with HIV compared to the general population |
Retrospective cohort |
Nizami et al.(2424. Nizami S, Morales C, Hu K, Holzman R, Rapkiewicz A. Trends in mortality from human immunodeficiency virus infection, 1984-2016: an autopsy-based study. Arch Pathol Lab Med. 2020;144(5):572-9.) |
252 autopsies of HIV-infected patients |
Analysis of autopsy records of HIV-infected patients |
|
To analyze trends in the cause of death of HIV-infected patients in a New York hospital |
Retrospective cohort |
Chammartin et al.(2525. Chammartin F, Lodi S, Logan R, Ryom L, Mocroft A, Kirk O, d’Arminio Monforte A, Reiss P, Phillips A, El-Sadr W, Hatleberg CI, Pradier C, Bonnet F, Law M, De Wit S, Sabin C, Lundgren JD, Bucher HC; D:A:D Study Group. Risk for Non-AIDS-Defining and AIDS-Defining Cancer of Early Versus Delayed Initiation of Antiretroviral Therapy: a Multinational Prospective Cohort Study. Ann Intern Med. 2021;174(6):768-76.) |
8,318 PLHIV between 2006 and 2016 |
Data collection on adverse events of antiretroviral therapy in PLHIV from Europe, Australia and United States of America |
|
To estimate the difference in long-term risk for cancer with immediate antiretroviral therapy strategy |
Retrospective cohort |
Arora et al.(2626. Arora S, Mahesh A, Mahesh NK, Verma N. Spectrum of malignancies among human immunodeficiency virus-infected patients at a tertiary level human immunodeficiency virus-anti-retroviral therapy center in a North Indian hospital. Indian J Sex Transm Dis AIDS. 2021;42(2):118-24.) |
1,258 PLHIV |
Retrospective and prospective analysis of PLHIV from a medical center in India for seven years |
|
To analyze the prevalence pattern and changing trends of neoplasms in PLHIV |
Retrospective cohort |
Neuhaus et al.(2727. Neuhaus J, Angus B, Kowalska JD, La Rosa A, Sampson J, Wentworth D, Mocroft A; INSIGHT SMART and ESPRIT study groups. Risk of all-cause mortality associated with nonfatal AIDS and serious non-AIDS events among adults infected with HIV. AIDS. 2010;24(5):697-706.) |
5,472 PLHIV (SMART study) 4,111 PLHIV (ESPIRIT study) |
Patients randomized to CD4-guided antiretroviral therapy or continuous use of antiretroviral therapy (SMART study) Patients randomized to interleukin-2 or continuous antiretroviral therapy (SPIRIT study) |
Continuous use of HAART (SMART) Continuous use of HAART alone (SPIRIT) |
To assess cumulative mortality six months after AIDS and non-AIDS-related events in two international studies |
Retrospective cohort |
Micheletti et al.(2828. Micheletti AR, Macedo AC, Silva GB, Silva AC, Silva-Vergara ML, Murta EF, et al. Benign and malignant neoplasias in 261 necropsies for HIV-positive patients in the period of 1989 to 2008. Rev Inst Med Trop Sao Paulo. 2011;53(6):309-14.) |
261 necropsies of patients diagnosed with HIV |
Analysis of necropsy information between 1989 and 2008 |
|
To evaluate an increase or decrease in the number of neoplasms after the introduction of HAART |
Retrospective cohort |